CeQur

Executive Summary

CeQur, a Swiss medical device company founded in 2005, addresses the burden of multiple daily injections for people with diabetes through its wearable insulin patch, CeQur Simplicity. The patch delivers mealtime insulin over several days, aiming to improve adherence and simplify diabetes management. As a private company with no disclosed financials, its progress hinges on regulatory clearances and market adoption. The product targets a significant unmet need in insulin delivery, competing with traditional injections and other patch-based systems. CeQur's success will depend on securing regulatory approvals, particularly in the US and Europe, and establishing commercial partnerships. With a focused product and clear value proposition, the company has moderate potential in the metabolic drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for CeQur Simplicity60% success
• Q2 2026CE Mark Renewal or Expansion for European Market70% success
• Q4 2026Strategic Partnership with Large Pharma for Distribution50% success